Translating microRNA to the Clinic reviews the possibilities of current methodological tools and experimental approaches used by leading translational researchers. The book features the uses of micro ribonucleic acid as deployed in cancer targeting in biomarkers, diabetes, cardiovascular disease, and neurodegeneration, among many others.
Pedagogically, the work concentrates on the latest knowledge, laboratory techniques, and experimental approaches used by translational research leaders in this field, promoting a cross-disciplinary communication between the sub-specialities of medicine, but in common with other books on the topic. In addition, the book emphasizes recent innovations, critical barriers to progress, the new tools that are being used to overcome them, and specific areas of research that require additional study to advance the field as a whole.
Dr Laurence is pursuing the pathophysiology of cardiovascular and skeletal abnormalities linked to HIV disease and its therapies at Weill Cornell. Dr Laurence is the editor-in-chief of Translational Medicine, which Elsevier co-publishes with the CSCTR.
1. Introduction to microRNAs (Monty Montano) 2. MicroRNA targets for cancer therapy (Carlo Croce, MD) 3. MicroRNAs as Targets for Lung Cancer Therapy and Prevention (Ethan Dmitrovsky, M.D.) 4. MicroRNAs as biomarkers in lung cancer: miracle or quagmire? (Robert Kratzke, MD) 5. MicroRNAs in inflammatory lung disease (Joe GN Garcia MD) 6. MicroRNAs and lung fibrosis (Naftali Kaminski MD) 7. MicroRNAs and diabetes (Romano Regazzi, PhD) 8. MicroRNAs and liver disease (Nicholas O. Davidson, MD; Kevin Korenblat, MD; Tom Kerr, MD, PhD) 9. MicroRNAs and cardiovascular disease (Gerald Dorn, MD) 10. MicroRNAs and diabetic nephropathy and vascular disease in kidney tissue (Bryan Becker, MD) 11. MicroRNAs and autoimmunity (Ansar Ahmed, DVM, PhD) 12. MicroRNAs and neurodegenerative diseases (Edgardo Rodriguez-Lebron, PhD) 13. MicroRNAs in viral hepatitis (TBA)